Liquidia Corporation
LQDANASDAQLiquidia's proprietary PRINT (Particle Replication In Non-wetting Templates) technology enables the production of uniform, precisely engineered drug particles for inhalation, improving drug delivery to the lungs.
Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-09-09. Published by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.
Filing figures as of June 30, 2026 · text updated 2026-09-09 · archived: kept for reference, not maintained · where each field comes from
Key figures from SEC filings
LQDA filings on EDGAR →Cash & investments
$284M
at June 30, 2026 (10-Q)
Quarterly operating burn
No burn
operating cash flow positive, Jan–Jun 2026
Cash runway
—
not a runway: funded by operations
Shares outstanding
89.5M
cover page of the latest filing
Read from LQDA's XBRL financial data; latest filing August 12, 2026; fetched 2026-09-28. Runway assumes the reported burn continues unchanged; burn usually rises as programs advance, so treat it as an upper bound. Revenue stage: Early revenue.
Upcoming catalysts
No upcoming catalyst for Liquidia Corporation has been confirmed against a primary source. Rather than estimate one, this section is left empty — check the company's investor relations page and ClinicalTrials.gov directly.
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| YUTREPIA (treprostinil) inhalation powder | Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) | Approved | Approved | ▼ |
| L606 (treprostinil liposomal inhalation) | Pulmonary Arterial Hypertension (PAH) | Phase 2 | Not disclosed | ▼ |
What does Liquidia Corporation do?
Liquidia Corporation is a small biotech company that makes a drug called YUTREPIA, which is used to treat a rare disease called pulmonary arterial hypertension (PAH). PAH is high blood pressure in the lungs, which makes it hard for the heart to pump blood. YUTREPIA is a powder that patients inhale to relax blood vessels in the lungs, making it easier to breathe. It's similar to an existing drug called Tyvaso, but YUTREPIA is more convenient because it uses a small, easy-to-use inhaler and requires fewer doses per day. Liquidia is also developing a new version called L606 that might only need to be taken once a day. The company is in a legal battle with United Therapeutics, the maker of Tyvaso, over patents. If Liquidia wins, it can sell YUTREPIA without restrictions; if it loses, it might have to pay damages or stop selling. For investors, the key is whether YUTREPIA can take market share from Tyvaso and whether L606 will be successful. The company is still losing money but has enough cash to operate for about two years. The stock is risky because of the legal issues and competition, but if things go well, the potential is significant.
What to watch
Monitor quarterly YUTREPIA sales growth and prescription trends.
Follow court rulings in the patent dispute with United Therapeutics.
Watch for L606 Phase 2 data and any updates on the PH-ILD approval timeline.
Investment thesis
High RiskBull case
Liquidia has a unique, FDA-approved product (YUTREPIA) that is gaining traction in the PAH market. The drug's dry powder formulation offers convenience advantages over competitors, potentially capturing significant market share. The company has a strong patent portfolio protecting YUTREPIA until 2035, and is actively defending its intellectual property against United Therapeutics. With a growing revenue stream and a pipeline that includes L606, a next-generation product, Liquidia has multiple shots on goal. The company is well-capitalized with a runway into 2027, and recent legal victories have removed overhangs. If YUTREPIA continues to ramp and L606 shows promise, the stock could re-rate significantly.
Bear case
Liquidia faces intense competition from United Therapeutics, which has a similar product (Tyvaso) with a larger sales force and established relationships. Legal battles with United Therapeutics could result in injunctions or damages that threaten YUTREPIA's market access. YUTREPIA's launch has been slower than expected, and the company is still burning cash. The PAH market is niche, and reimbursement challenges could limit growth. Additionally, L606 is still in early stages, and clinical trials may fail or be delayed. With a small market cap, the stock is volatile and susceptible to negative headlines.
Risk factors
Patent litigation with United Therapeutics could result in injunctions or damages that limit YUTREPIA's commercialization.
YUTREPIA's market share growth may be slower than expected due to competition and physician prescribing habits.
Clinical development of L606 may face delays or failures, consuming cash and reducing future prospects.
Comparable companies
Sponsored
Get premium LQDA analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you